MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$26,023K
EPS
-$0.3
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
19,027
15,703
18,173*
15,695
General and administrative
8,993
6,630
12,580*
5,953
Total operating expenses
28,020
22,333
30,753
21,648
Operating loss
-28,020
-22,333
-30,753*
-21,648
Loss on long-term investment
0
-
-1,637*
-
Other expense, net
-6
-1
17*
-9
Interest expense
14
17
25*
22
Interest income
2,194
2,113
2,044*
1,456
Amortization of premium on investments in u.s. treasury securities
-
-
-
60
(amortization of premium) accretion of discount on investments in u.s. treasury securities, net
-21
42
-28*
-
Total other income and expense
2,153
2,137
371*
1,365
Loss from operations before income taxes
-25,867
-20,196
-30,382
-20,283
Net loss
-25,867
-20,196
-30,382
-20,283
Net unrealized gain (loss) on investments in u.s. treasury securities
-156
-330
-
-
Total other comprehensive gain (loss)
-156
-330
-
-
Comprehensive loss
-26,023
-20,526
-
-
Basic EPS
-0.3
-0.25
-0.539
-0.33
Diluted EPS
-0.3
-0.25
-0.539
-0.33
Basic Average Shares
85,626,751
81,183,812
56,381,474
60,980,867
Diluted Average Shares
85,626,751
81,183,812
56,381,474
60,980,867
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$26,023K
Net loss
-$25,867K
(0.90%↑ Y/Y)
Total other
comprehensive gain (loss)
-$156K
Interest income
$2,194K
(73.03%↑ Y/Y)
Loss from operations
before income taxes
-$25,867K
(0.90%↑ Y/Y)
Net unrealized gain
(loss) on investments...
-$156K
Total other income and
expense
$2,153K
(-53.04%↓ Y/Y)
(amortization of premium)
accretion of discount on...
-$21K
Interest expense
$14K
(-44.00%↓ Y/Y)
Other expense, net
-$6K
(57.14%↑ Y/Y)
Operating loss
-$28,020K
(8.69%↑ Y/Y)
Total operating
expenses
$28,020K
(-8.69%↓ Y/Y)
Research and development
$19,027K
(29.25%↑ Y/Y)
General and
administrative
$8,993K
(-43.68%↓ Y/Y)
Buy us a coffee
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)